a 30-amino-acid sequence at the C terminus of CPE which possesses most, if not all, receptor-binding activity associated with enterotoxin ( Fig. 1 ). Recombinant and synthetic peptide homologs corresponding to the 30-mer sequence (termed CPE290-319) have been shown to block specific binding of native CPE to the enterotoxin receptor (6) . These CPE290_319 homologs are not cytotoxic, but preincubation of Vero cells with recombinant or synthetic CPE29-319 prior to CPE challenge blocks native CPE cytotoxicity through receptor competition. Recent studies (7) have also shown that there is at least one (and possibly more) neutralizing epitope associated with the CPE29,-319 region, since polyclonal antibodies prepared against native CPE were shown to (i) react with CPE290_319 recombinant and synthetic peptide homologs, (ii) block the binding of both CPE290319 and native enterotoxin to mammalian receptors, and (iii) neutralize native enterotoxin cytotoxicity.
Production of antitoxin immunity is an important component of several approved and effective bacterial vaccines (e.g., the diphtheria-pertussis-tetanus vaccine). Vaccines which protect against toxin-mediated bacterial diseases often work by eliciting a strong antitoxin response involving antibodies which block toxin binding to mammalian cells. Similar results (24) demonstrate that CPE cytotoxicity also can be neutralized by antibodies which abolish enterotoxin binding. Since CPE29,_319 contains a binding-neutralizing epitope and is not cytotoxic itself, these results collectively suggest that CPE290-319 might serve as a candidate for the development of a toxoid vaccine to protect against CPEmediated disease. However, if CPE29,a319 is to be useful for vaccine development, it must elicit a strong immune response, involving antibodies capable of neutralizing native enterotoxin. The present study demonstrates that a CPE290_319 synthetic peptide homolog conjugated to a thyroglobulin carrier can elicit a neutralizing antienterotoxin response in mice.
Short synthetic peptides such as CPE29,-319 are often poorly immunogenic (11) . However, the immune response to a peptide can routinely be improved by conjugating the peptide to a protein carrier (e.g., thyroglobulin) (4). A synthetic peptide homolog of CPE290_319 (Fig. 1 ) containing one additional cysteine residue at its N terminus was prepared by previously described methods (6) . The sulfhydryl side chain of this cysteine was used as a target for conjugation to the epsilon amino groups of the carrier protein thyroglobulin by using the heterobifunctional cross-linker m-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) (Pierce Chemical, Rockford, Ill.). MBS was chosen as a cross-linker for several reasons, including the following: (i) it has been used previously in similar conjugation procedures which elicited antipeptide antibody responses (4, 20) (5) (6) (7) (8) .
protein was separated from unbound cross-linker by gel filtration over a Sephadex G-10 column (Pharmacia LKB, Piscataway, N.J.) by using 0.1 M phosphate, pH 6.0, as an eluent. The CPE290319 homolog containing an additional N-terminal cysteine was dissolved in 0.1 M borate, pH 9.1, at a concentration of 1 mg/ml, and the sulfhydryl group on the cysteine was reduced by exposure to 5 ,uM fresh NaBH4. After 5 min, the NaBH4 was inactivated by acidification with HC1. The peptide solution was neutralized with NaOH, and 5 ml of solution was combined with the activated thyroglobulin carrier. After overnight incubation of this mixture at 24°C with sample stirring, free peptide was removed from the thyroglobulin-peptide conjugate by gel filtration over a Sephadex G-25 column (Pharmacia LKB) with PBS as an eluent. The efficacy of coupling was assessed by amino acid composition analysis, and it was determined that approximately 30 mol of peptide was conjugated per mol of thyroglobulin. These levels of peptide coupling are typical for thyroglobulin conjugates which have been used successfully to obtain antipeptide antibodies (4) .
Female BALB/c mice (Zivic-Miller Laboratories, Pittsburgh, Pa.) each received three intraperitoneal injections given at 2-week intervals. Three mice were immunized throughout the study with CPE290319-thyroglobulin conjugate. Each mouse in this group received 0.2-ml injections containing conjugate (25 p,g) dissolved in 100 ,u of sterile PBS plus 100 ,u of either Freund's complete adjuvant (first injection only) or Freund's incomplete adjuvant (last two injections). Similarly, three mice received a series of three 0.2-ml injections of thyroglobulin (25 ,ug) dissolved in 100 ,ul of PBS plus 100 ,u of either Freund's complete or Freund's incomplete adjuvant, given as described above for conjugate. Mock-immunized mice received three injections, each containing 100 ,ul of PBS plus 100 RI of Freund's complete or incomplete adjuvant, also given as for conjugate. Ten days after the third immunization, all mice were periorbitally bled. The resultant sera were heated at 56°C for 30 min to inactivate complement prior to use.
To detect an antibody response following this immunization protocol, immuno-dot blot analysis was performed with each mouse serum by previously described methods (6, 7) . These experiments (Fig. 2) Sera from all three mice immunized with CPE290-319-thyroglobulin conjugate recognized conjugate. Importantly, these sera also reacted with native CPE and nonconjugated CPE290319 synthetic peptide but did not react with either thyroglobulin or a negative-control peptide corresponding to a sequence from hen egg lysozyme (6) . Also To assess whether the antibodies in the conjugate-immunized sera were capable of specifically neutralizing native CPE cytotoxicity, a 86Rb release Vero cell assay of CPE cytotoxicity was used (6, 13, 18) . Native enterotoxin (5 jig) was preincubated for 15 min at 37°C in 2 ml of Hanks' balanced salt solution with or without 5, 20, or 50 ,ul of the specified mouse serum. Each preincubation mixture was then added to a confluent Vero cell culture which had been 86Rb labeled, as described previously (6, 13, 18 After 2 h, the serum was removed, the blots were washed, and bound mouse antibodies were detected as described previously (6) Results shown in Fig. 3 (Fig. 3) assay conditions used for Fig. 3 experiments (data not  shown) .
These results demonstrate that the sera from the conjugate-immunized mice could specifically neutralize CPE cytotoxicity. As mentioned, the CPE29,_319 sequence has been implicated in enterotoxin binding, and antibodies which react with CPE29,-319 block native enterotoxin binding (6), so it might be expected that the sera from conjugateimmunized mice would block native CPE binding. This prediction was tested experimentally b using an 1I-CPEspecific binding assay (6) . Briefly, 1 I-CPE (1 ,ug) was preincubated in the presence or absence of the specified serum (either 4 or 40 ,ul) for 30 min at 37°C. Half of each preincubation mixture then received a 50-fold excess of unlabeled CPE (to determine nonspecific binding; see below). All mixtures were then added to rabbit intestinal brush border membranes (100 ,ug of protein), prepared as described previously (6) . After 30 min at 24°C, membranes were pelleted and washed twice to remove unbound CPE. Sample radioactivity was determined with a Packard gamma counter. Specific binding is calculated as the difference between radioactivity in total binding samples (i.e., no unlabeled CPE added) and nonspecific binding samples (i.e., samples receiving excess unlabeled CPE). 
